{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133133","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.342786+00:00","generated_at":"2026-06-02T19:41:47.370173+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biote reports Q1 revenue $46.8M (+4.4%), net loss narrows to $5.8M; reaffirms 2024 guidance","bullets":["Revenue $46.8M (+4.4% YoY); procedure revenue $37.4M (+6.6%).","Net loss $(5.8)M vs $(21.4)M prior year; EPS $(0.06) vs $(0.39).","Adjusted EBITDA $14.2M (+8.0%); margin 30.2% (+100bps).","Gross margin 71.4% (+240bps) on improved mix.","BioteRx launch progressing; reaffirms FY2024 guidance with H2 acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133133","json":"https://secwatch.observer/filing/0001193125-24-133133.json","markdown":"https://secwatch.observer/filing/0001193125-24-133133.md","text":"https://secwatch.observer/filing/0001193125-24-133133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524133133/0001193125-24-133133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524133133/d802970d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:41:47.370173+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a760f065d403b9259696f6935531c71f8c835859","claim":"biote Corp. reported first quarter ended March 31, 2024 results: revenue Revenue of $46.8 million, net income Net loss of $(5.8) million, EPS basic and diluted loss per share attributable to biote Corp. stockholders of $(0.06). Guidance reaffirmed.","evidence_excerpt":"for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $46.8 million, up 4.4% • Procedure revenue of $37.4 million, up 6.6% • Gross profit margin of 71.4%, an approximately 240-basis point increase • Net loss of $(5.8) million, representing net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524133133/0001193125-24-133133-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"Revenue of $46.8 million"},{"label":"Net income","value":"Net loss of $(5.8) million"},{"label":"EPS","value":"basic and diluted loss per share attributable to biote Corp. stockholders of $(0.06)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}